Digestive diseases and sciences · 2026
Pancrelipase Improves Symptoms of Exocrine Pancreatic Insufficiency and Health-Related Quality of Life in a Real-World Population of Patients with Chronic Pancreatitis.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Othman Mohamed O, Kort Jens J, Ramsey Mitchell L, Gonda Tamas A, Lara Luis F, Jazrawi Saad, Keihanian Tara, Park Walter, Brett Neil R, Harb Diala, Li Moming, Trikudanathan Guru
Аннотация
PURPOSE: Treatment for exocrine pancreatic insufficiency (EPI) includes pancreatic enzyme replacement therapy (PERT). Although PERT may improve symptoms, there are currently no EPI symptom measures to monitor PERT treatment. This analysis evaluated the utility of the Pancreatic Exocrine Insufficiency Questionnaire (PEI-Q) in patients with chronic pancreatitis and EPI treated with pancrelipase.
METHODS: This prospective, observational study (NCT04949828) included adult patients with chronic pancreatitis and EPI who were recommended pancrelipase 72,000 lipase units per meal and 36,000 lipase units per snack by an independent physician. Outcomes included the change from baseline to 1 month and 3 months after treatment initiation in PEI-Q symptom score, PEI-Q symptom severity categories, and health-related quality of life (HRQoL) as measured by the PEI-Q impact domain score.
RESULTS: The per-protocol population included 32 and 29 patients with data at 1 and 3 months after pancrelipase initiation, respectively. A significant reduction in mean PEI-Q symptom scores was observed from baseline to 1 month (- 1.0; p < 0.001) and 3 months (- 1.1; p < 0.001). Despite all patients having moderate/severe EPI symptoms at baseline, 62.5% and 62.1% of patients reported mild/no EPI symptoms after 1 and 3 months, respectively. There was also a significant reduction in mean PEI-Q impact scores from baseline to 1 month (- 1.0; p < 0.001) and 3 months (- 1.2; p < 0.001), indicating improved HRQoL.
CONCLUSION: Pancrelipase improved patient-reported EPI symptoms and HRQoL based on the PEI-Q, which may be a useful tool for monitoring PERT treatment in patients with chronic pancreatitis and EPI.
METHODS: This prospective, observational study (NCT04949828) included adult patients with chronic pancreatitis and EPI who were recommended pancrelipase 72,000 lipase units per meal and 36,000 lipase units per snack by an independent physician. Outcomes included the change from baseline to 1 month and 3 months after treatment initiation in PEI-Q symptom score, PEI-Q symptom severity categories, and health-related quality of life (HRQoL) as measured by the PEI-Q impact domain score.
RESULTS: The per-protocol population included 32 and 29 patients with data at 1 and 3 months after pancrelipase initiation, respectively. A significant reduction in mean PEI-Q symptom scores was observed from baseline to 1 month (- 1.0; p < 0.001) and 3 months (- 1.1; p < 0.001). Despite all patients having moderate/severe EPI symptoms at baseline, 62.5% and 62.1% of patients reported mild/no EPI symptoms after 1 and 3 months, respectively. There was also a significant reduction in mean PEI-Q impact scores from baseline to 1 month (- 1.0; p < 0.001) and 3 months (- 1.2; p < 0.001), indicating improved HRQoL.
CONCLUSION: Pancrelipase improved patient-reported EPI symptoms and HRQoL based on the PEI-Q, which may be a useful tool for monitoring PERT treatment in patients with chronic pancreatitis and EPI.